NCT06328764View on ClinicalTrials.gov

CS-101 in Patients With β-thalassemia

EARLY_PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 19, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

January 30, 2026

Conditions
Beta-Thalassemia
Interventions
GENETIC

CS-101

Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique

Trial Locations (1)

Unknown

The First Affiliated Hospital of Guangxi Medical University, Nanning

Sponsors
All Listed Sponsors
collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

lead

CorrectSequence Therapeutics Co., Ltd

INDUSTRY